ALCLS Cellectis SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) --

 

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares

in the capital		Total number of voting rights
12/31/202371,751,20177,686,718

For further information on Cellectis, please contact:     

Media contact:       

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,   

Investor Relations contacts:       

Arthur Stril, Chief Business Officer, +1 (347) 809 5980,        

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577  

Attachment



EN
08/01/2024

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights04/30/202471,955,53577,891,229 For further information on Cellectis, please contact:      Media contact:        Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,    Investor Relations cont...

15h / 58m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 mai 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote30/04/202471 955 53577 891 229 Pour de plus amples informations sur Cellectis, veuillez contacter :         Contact média :         Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, ...

15h / 58m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Announces Completion of the Additional Equity Investment by ...

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (LSE/STO/Nasdaq: AZN) co...

May 6, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis annonce la réalisation de l’investissement additionnel d’Ast...

Cellectis annonce la réalisation de l’investissement additionnel d’AstraZeneca Réalisation de l’investissement additionnel de 140 millions de dollars d’AstraZeneca tel qu’annoncé le 1er et le 15 novembre 2023 NEW YORK, 06 mai 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a annoncé aujourd'hui, que, à la suite de de l'approbation du ministère français de l'économie et de la satisfaction des autres conditions suspensives, AstraZeneca (LSE/STO/Nasdaq : AZN) a réalisé l’investissement additionnel de 140 millions de dollars dans la Société tel que précédemment a...

May 6, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the resignation of Mr. Bing Wang from his position of the Company with immediate effect, and the concomitant appointment of Mr. Arthur Stril as interim Chief Financial Officer, replacing Mr. Bing Wang. Mr. Stril joined Cellectis in 2018 as Vice President, Corporate Devel...

May 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch